Shares of AngioDynamics (NASDAQ: ANGO) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter update.
AngioDynamics reported fiscal Q1 net sales of $67.5 million, up 1.1% year over year. This result was a little lower than the average analysts' revenue estimate of $67.93 million.
The company posted a net loss of $12.8 million, or $0.31 per share, based on generally accepted accounting principles (GAAP). Its adjusted net loss was $4.4 million, or $0.11 per share -- better than the consensus estimate of an adjusted loss of $0.15 per share.
Some good news for AngioDynamics
The company did have some good news recently. Last month, it submitted to the U.S. Food and Drug Administration (FDA) the results from a pivotal study of the NanoKnife system for ablation of prostate tissue in intermediate-risk patients. AngioDynamics hopes to win a 510(k) clearance based on this filing.
The company also received European CE Mark approval for its Auryon Atherectomy System in treating peripheral artery disease. This system was cleared by the FDA in 2020.
Also, despite the mixed results for AngioDynamics in its fiscal Q1, the medical technology company maintained its previous full-year guidance. AngioDynamics continues to expect net sales of between $282 million and $288 million, reflecting year-over-year growth of 4.2% to 6.4%. It also projects bottom-line improvement with an adjusted net loss per share of between $0.38 and $0.42 compared to a pro forma adjusted loss per share of $0.45 in fiscal 2024.
Buy AngioDynamics stock on the dip?
Some investors could be tempted to scoop up shares of AngioDynamics after its latest pullback. However, the company's growth isn't anything to get excited about. I think many other stocks offer more attractive risk-reward propositions.
Should you invest $1,000 in AngioDynamics right now?
Before you buy stock in AngioDynamics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AngioDynamics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $728,325!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of September 30, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
